IIM
NKTR icon

INTECH Investment Management’s Nektar Therapeutics NKTR Stock Holding History

INTECH Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$449K Buy
+6,426
New +$470K ﹤0.01% 1393
2025
Q2 		– Sell
-7,799
Closed -$79.6K – 2598
2025
Q1 		$79.6K Buy
7,799
+2,343
+43% +$30.6K ﹤0.01% 2363
2024
Q4 		$76.1K Buy
5,456
+3,373
+162% +$59.5K ﹤0.01% 2266
2024
Q3 		$40.6K Buy
+2,083
New +$39.7K ﹤0.01% 1998

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

INTECH Investment Management's NKTR Position: Q2 2026 in Review

INTECH Investment Management opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 6,426 shares worth $449K. The stake represents ﹤0.01% of the portfolio and ranks #1393 among its holdings. This is a return to the name: INTECH Investment Management previously reported a position in NKTR as recently as Q1 2025.

INTECH Investment Management first reported a position in NKTR in Q3 2024 and has held it in 4 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • INTECH Investment Management held 6,426 shares of Nektar Therapeutics worth $449K as of Q2 2026.
  • Nektar Therapeutics was a new INTECH Investment Management position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1393 holding.
  • INTECH Investment Management first reported a position in Nektar Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.